• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Neurology

Acute lymphoblastic leukemia disease burden associated with safety and efficacy of CD19-CAR therapy

byShani ChibberandDayton McMillan
February 2, 2018
in Neurology, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Patients with a higher disease burden of acute lymphoblastic leukemia (ALL) treated with CD19-specific chimeric antigen receptor (CAR) T cell therapy experienced greater incidences of cytotoxic release syndrome and neurotoxicity compared to low disease burden patients.

2. Patients with high disease burden had shorter overall survival times compared to low disease burden patients.

Evidence Rating Level: 2 (Good)

Study Rundown: Relapsed and refractory ALL continues to be difficult to treat, with poor overall survival rates using standard chemotherapy and biologic regimens. CD19-CAR therapy has been investigated as a potential therapy for patients with refractory B-cell cancers, showing promise over limited periods of follow-up. This reports longer term follow-up of a phase 1 trial assessing safety and efficacy of CD19-CAR therapy in a cohort of adults with relapsed or refractory ALL. Safety outcomes of this study included incidences of cytotoxic release syndrome and neurotoxic adverse events, which occurred in the majority of patients and at a higher incidence in patients with higher disease burden. Secondary efficacy outcomes included overall survival rates and complete remission rates, which showed longer overall survival relative to many biologic therapy treated relapsed ALL patients. Overall survival was also greater in patients with lower ALL disease burden.

Strengths of the study include its extensive subgroup analysis by disease burden and extended follow-up for a novel treatment regiment, while its main limitation is the study size and power associated with the phase 1 design.

Click to read the study, published in NEJM

Relevant Reading: CD19-Targeted CAR T Cells as Novel Cancer Immunotherapy for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

RELATED REPORTS

The OVIVA trial: Oral versus intravenous antibiotics for bone and joint infection [Classics Series]

Inactivated whole-virion SARS-CoV-2 vaccine reduces rates of symptomatic COVID-19 infections [Classics Series]

The COVE trial: mRNA-1273 vaccine for preventing COVID-19 [Classics Series]

In-Depth [prospective cohort]: This phase 1 clinical trial enrolled 83 adult patients between 2010 and 2016 with either relapsed or refractory B-cell ALL. A total of 53 patients later received 19-28z CAR T-cell infusion therapy. Safety outcomes, incidence of cytotoxic release syndrome and neurotoxic effects, were both graded on a numeric scale and considered severe with a grade of 3 or higher. Efficacy outcomes included complete remission rates, defined as less than 5% bone marrow blasts or absence of blasts, and overall survival rates.

Severe cytokine release syndrome occurred in 14 of 53 patients (26%; 95% confidence interval [CI], 15-40%), with 45 of 53 patients experiencing any grade of cytokine release syndrome (85%; 95%CI, 72-93%). One patient died from severe cytokine release syndrome. Grade three neurotoxicity occurred in 19 patients (36%) and 3 patients were noted to have grade 4 toxicity (6%). Patients with higher disease burden (defined as having five percent or greater bone marrow blasts or extramedullary disease) had higher rates of severe cytokine release syndrome (41 % for high burden vs 5% for low burden; p = 0.004) and neurotoxic effects (59 % for high burden vs 14% for low burden; p = 0.002) compared to patients with low disease burden. Median event-free survival among all patients was 6.1 months (95%CI, 5.0 to 11.5 months) after a median follow-up of 29 months.  When stratified by disease burden, patients with low disease burden had significantly longer overall survival compared to patients with high disease burden (median overall survival 20.1 months vs 12.4 months; p = 0.02).

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: acute lymphoblastic leukemiaadverse events
Previous Post

Isolated left axis deviation may not necessitate further work up

Next Post

Catheter ablation of atrial fibrillation in heart failure reduces mortality and hospitalization: The CASTLE-AF trial

RelatedReports

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Neurology Classics

The OVIVA trial: Oral versus intravenous antibiotics for bone and joint infection [Classics Series]

September 14, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
COVID-19 Classics

Inactivated whole-virion SARS-CoV-2 vaccine reduces rates of symptomatic COVID-19 infections [Classics Series]

August 3, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
COVID-19 Classics

The COVE trial: mRNA-1273 vaccine for preventing COVID-19 [Classics Series]

July 15, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
COVID-19 Classics

5-day versus 10-day course of remdesivir in patients with severe COVID-19 [Classics Series]

July 12, 2022
Next Post
Radiation dose associated with increased heart disease in Hodgkin lymphoma survivors

Catheter ablation of atrial fibrillation in heart failure reduces mortality and hospitalization: The CASTLE-AF trial

Pediatric reptile-associated salmonellosis a substantial burden

Recurrent Salmonella enterica Typhimurium infection disables host protection against intestinal inflammation [PreClinical]

Improved islet encapsulation device for the treatment of type 1 diabetes [PreClinical]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Higher body mass index may be associated with altered vitamin D levels and metabolism
  • #VisualAbstract: Torsemide does not provide additional decrease in mortality compared to furosemide among patients hospitalized for heart failure
  • Community-based adult vision screening program increases access to eye care
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options